Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Purchased by Braidwell LP

Braidwell LP grew its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 144.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,206,589 shares of the company's stock after acquiring an additional 712,902 shares during the quarter. Braidwell LP owned about 4.08% of Dianthus Therapeutics worth $26,304,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. BNP Paribas Financial Markets bought a new position in Dianthus Therapeutics in the fourth quarter worth about $59,000. Allostery Investments LP acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter worth $545,000. Ally Bridge Group NY LLC acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter worth $2,320,000. TCG Crossover Management LLC purchased a new position in Dianthus Therapeutics during the 4th quarter worth $32,735,000. Finally, Northern Trust Corp increased its position in Dianthus Therapeutics by 21.2% during the 4th quarter. Northern Trust Corp now owns 245,523 shares of the company's stock valued at $5,352,000 after buying an additional 42,923 shares in the last quarter. 47.53% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Wedbush reissued an "outperform" rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. HC Wainwright reissued a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, Dianthus Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $54.33.

Dianthus Therapeutics Stock Performance

NASDAQ DNTH traded down $1.03 on Friday, reaching $19.59. 209,703 shares of the company's stock traded hands, compared to its average volume of 266,739. The stock has a 50 day moving average price of $19.83 and a 200-day moving average price of $22.44. The firm has a market cap of $629.35 million, a price-to-earnings ratio of -7.84 and a beta of 1.48. Dianthus Therapeutics, Inc. has a fifty-two week low of $13.37 and a fifty-two week high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The company had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.40 million. As a group, equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.